Literature DB >> 10493503

Preoperative diagnosis of thyroid papillary and anaplastic carcinomas by real-time quantitative reverse transcription-polymerase chain reaction of oncofetal fibronectin messenger RNA.

T Takano1, A Miyauchi, T Yokozawa, F Matsuzuka, I Maeda, K Kuma, N Amino.   

Abstract

The restricted expression of oncofetal fibronectin (onfFN) mRNA in thyroid papillary and anaplastic carcinomas was recently reported. In this study, we measured the copy number of onfFN mRNA in RNAs extracted from fine needle aspiration biopsies by real-time quantitative reverse transcription-PCR using thyroglobulin mRNA as an internal control. By measuring the onfFN:thyroglobulin mRNA ratio, preoperative aspirates from 31 papillary carcinomas and an anaplastic carcinoma can be distinguished from those from 5 adenomatous goiters, 5 follicular adenomas, and 4 follicular carcinomas. Thus, quantification of onfFN by real-time quantitative reverse transcription-PCR may be useful for the preoperative diagnosis of papillary and anaplastic carcinomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493503

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a new diagnostic tool in patients with biliary strictures.

Authors:  Hans Dieter Nischalke; Volker Schmitz; Carolin Luda; Katharina Aldenhoff; Cordula Berger; Georg Feldmann; Tilman Sauerbruch; Ulrich Spengler; Jacob Nattermann
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

3.  Transcriptional activity of the 5'-flanking region of the thyroid transcription factor-1 gene in human thyroid cell lines.

Authors:  Hiroya Yamada; Toru Takano; Fumio Matsuzuka; Mikio Watanabe; Akira Miyauchi; Yoshinori Iwatani
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

4.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

Authors:  Krzysztof Fujarewicz; Michal Jarzab; Markus Eszlinger; Knut Krohn; Ralf Paschke; Małgorzata Oczko-Wojciechowska; Małgorzata Wiench; Aleksandra Kukulska; Barbara Jarzab; Andrzej Swierniak
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

5.  Gene expression profiles in thyroid carcinomas.

Authors:  T Takano; Y Hasegawa; F Matsuzuka; A Miyauchi; H Yoshida; T Higashiyama; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

6.  Quantitative measurement of thyroglobulin mRNA in peripheral blood of patients after total thyroidectomy.

Authors:  T Takano; A Miyauchi; H Yoshida; Y Hasegawa; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

7.  Determination of Suitable RT-qPCR Reference Genes for Studies of Gene Functions in Laodelphax striatellus (Fallén).

Authors:  Wei Wu; Haoqiu Liu; Yan Dong; Yun Zhang; Sek-Man Wong; Changchun Wang; Yijun J Zhou; Qiufang Xu
Journal:  Genes (Basel)       Date:  2019-11-04       Impact factor: 4.096

8.  IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC).

Authors:  Petra Richter; Kerstin Junker; Marcus Franz; Angela Berndt; Christiane Geyer; Mieczyslaw Gajda; Hartwig Kosmehl; Alexander Berndt; Heiko Wunderlich
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-03       Impact factor: 4.553

9.  High-throughput differential screening of mRNAs by serial analysis of gene expression: decreased expression of trefoil factor 3 mRNA in thyroid follicular carcinomas.

Authors:  T Takano; A Miyauchi; H Yoshida; K Kuma; N Amino
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.